Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) have received an average rating of “Moderate Buy” from the thirteen analysts that are presently covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $192.75.

A number of research firms have issued reports on JAZZ. StockNews.com downgraded shares of Jazz Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday. Stifel Nicolaus raised their price objective on shares of Jazz Pharmaceuticals from $225.00 to $230.00 and gave the company a “buy” rating in a research note on Friday, March 15th. HC Wainwright reiterated a “buy” rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a research report on Friday. UBS Group reduced their price target on Jazz Pharmaceuticals from $135.00 to $131.00 and set a “neutral” rating on the stock in a research report on Friday, March 1st. Finally, JPMorgan Chase & Co. upped their price objective on Jazz Pharmaceuticals from $170.00 to $190.00 and gave the company an “overweight” rating in a report on Friday, March 22nd.

Insider Activity

In related news, CFO Philip L. Johnson bought 12,000 shares of the company’s stock in a transaction on Friday, March 1st. The shares were purchased at an average cost of $119.65 per share, for a total transaction of $1,435,800.00. Following the acquisition, the chief financial officer now owns 27,932 shares of the company’s stock, valued at approximately $3,342,063.80. The purchase was disclosed in a filing with the SEC, which is available at this link. In related news, CFO Philip L. Johnson bought 12,000 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, March 1st. The stock was purchased at an average cost of $119.65 per share, with a total value of $1,435,800.00. Following the purchase, the chief financial officer now owns 27,932 shares in the company, valued at $3,342,063.80. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CAO Patricia Carr sold 1,936 shares of Jazz Pharmaceuticals stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $119.64, for a total value of $231,623.04. Following the completion of the sale, the chief accounting officer now directly owns 8,364 shares in the company, valued at approximately $1,000,668.96. The disclosure for this sale can be found here. 4.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Several institutional investors have recently bought and sold shares of JAZZ. Vestal Point Capital LP bought a new stake in shares of Jazz Pharmaceuticals in the fourth quarter worth $89,175,000. Armistice Capital LLC boosted its stake in shares of Jazz Pharmaceuticals by 108.4% during the 4th quarter. Armistice Capital LLC now owns 651,626 shares of the specialty pharmaceutical company’s stock worth $80,150,000 after buying an additional 338,882 shares during the last quarter. Los Angeles Capital Management LLC grew its holdings in shares of Jazz Pharmaceuticals by 558.6% in the 3rd quarter. Los Angeles Capital Management LLC now owns 322,775 shares of the specialty pharmaceutical company’s stock valued at $41,780,000 after acquiring an additional 273,764 shares in the last quarter. Pacer Advisors Inc. increased its position in shares of Jazz Pharmaceuticals by 28.1% in the fourth quarter. Pacer Advisors Inc. now owns 1,023,706 shares of the specialty pharmaceutical company’s stock valued at $125,916,000 after acquiring an additional 224,865 shares during the last quarter. Finally, Thompson Siegel & Walmsley LLC raised its holdings in Jazz Pharmaceuticals by 242.8% during the third quarter. Thompson Siegel & Walmsley LLC now owns 270,574 shares of the specialty pharmaceutical company’s stock worth $35,023,000 after acquiring an additional 191,648 shares in the last quarter. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Performance

JAZZ stock opened at $110.01 on Friday. The stock has a market capitalization of $6.94 billion, a PE ratio of 22.68, a price-to-earnings-growth ratio of 1.51 and a beta of 0.63. The company has a debt-to-equity ratio of 1.38, a current ratio of 2.27 and a quick ratio of 1.85. The company has a 50 day moving average price of $116.44 and a 200 day moving average price of $121.02. Jazz Pharmaceuticals has a fifty-two week low of $103.01 and a fifty-two week high of $146.70.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 earnings per share for the quarter, missing analysts’ consensus estimates of $4.44 by ($0.04). The firm had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1.01 billion. Jazz Pharmaceuticals had a return on equity of 27.86% and a net margin of 8.61%. Analysts forecast that Jazz Pharmaceuticals will post 16.24 EPS for the current year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.